Evelo Biosciences, Inc. Common Stock
EVLO
EVLO was delisted on the 11th of December, 2023.
39 hedge funds and large institutions have $15.5M invested in Evelo Biosciences, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 10 closing their positions.
11% less funds holding
Funds holding: 44 → 39 (-5)
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
89% less capital invested
Capital invested by funds: $140M → $15.5M (-$125M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $21K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JFG
Jefferies Financial Group
New York
|
+$57.9K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$29.4K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$24.3K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$20.8K |
| 5 |
VF
Virtu Financial
New York
|
+$18.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$487K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$179K |
| 3 |
6CM
683 Capital Management
New York
|
-$145K |
| 4 |
Bessemer Group
Woodbridge,
New Jersey
|
-$99K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$84.8K |
EVLO Hedge Fund Activity: Q1 2023 in Review
39 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Evelo Biosciences, Inc. Common Stock (EVLO) for Q1 2023, worth a combined $15.5M — down 89% from $140M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of EVLO and 5 opened new positions — a net loss of 5 holders — while 10 trimmed existing stakes and 8 added.
The largest buyer was Jefferies Financial Group, opening a new position worth an estimated $57.9K. The largest seller was CVI Holdings, cutting an estimated $487K.
- 39 institutional investors held Evelo Biosciences, Inc. Common Stock (EVLO) as of Q1 2023, down from 44 in Q4 2022.
- Funds reported $15.5M of Evelo Biosciences, Inc. Common Stock stock for Q1 2023, down 89% quarter-over-quarter.
- 5 funds opened new Evelo Biosciences, Inc. Common Stock positions in Q1 2023 and 10 closed out, a net change of -5 holders.
- The largest Evelo Biosciences, Inc. Common Stock buyer in Q1 2023 was Jefferies Financial Group, an estimated $57.9K added.
- The largest Evelo Biosciences, Inc. Common Stock seller in Q1 2023 was CVI Holdings, an estimated $487K sold.
Based on aggregated 13F filings for Q1 2023.